Tributary Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $9.73M | Sell |
308,587
-23,392
| -7% | -$737K | 0.86% | 58 |
|
|
2025
Q1 | $10.9M | Sell |
331,979
-11,983
| -3% | -$392K | 0.95% | 55 |
|
|
2024
Q4 | $12.4M | Sell |
343,962
-357
| -0.1% | -$12.9K | 0.96% | 56 |
|
|
2024
Q3 | $10.7M | Sell |
344,319
-802
| -0.2% | -$25K | 0.83% | 55 |
|
|
2024
Q2 | $9.23M | Buy |
345,121
+283
| +0.1% | +$7.57K | 0.77% | 58 |
|
|
2024
Q1 | $11.8M | Sell |
344,838
-1,423
| -0.4% | -$48.5K | 0.96% | 54 |
|
|
2023
Q4 | $10M | Sell |
346,261
-6,168
| -2% | -$179K | 0.84% | 60 |
|
|
2023
Q3 | $9.72M | Buy |
352,429
+4,189
| +1% | +$115K | 0.92% | 59 |
|
|
2023
Q2 | $10.5M | Sell |
348,240
-5,431
| -2% | -$163K | 0.94% | 55 |
|
|
2023
Q1 | $12.8M | Buy |
353,671
+11,445
| +3% | +$415K | 1.19% | 42 |
|
|
2022
Q4 | $12.2M | Sell |
342,226
-12,798
| -4% | -$456K | 1.22% | 44 |
|
|
2022
Q3 | $12M | Sell |
355,024
-5,459
| -2% | -$185K | 1.26% | 39 |
|
|
2022
Q2 | $10.4M | Buy |
360,483
+23,637
| +7% | +$684K | 1.04% | 51 |
|
|
2022
Q1 | $10.9M | Buy |
336,846
+16,104
| +5% | +$520K | 0.86% | 57 |
|
|
2021
Q4 | $9.35M | Sell |
320,742
-19,875
| -6% | -$580K | 0.71% | 62 |
|
|
2021
Q3 | $9.08M | Buy |
340,617
+39,478
| +13% | +$1.05M | 0.7% | 63 |
|
|
2021
Q2 | $9.27M | Sell |
301,139
-14,102
| -4% | -$434K | 0.7% | 60 |
|
|
2021
Q1 | $8.25M | Buy |
+315,241
| New | +$8.25M | 0.64% | 60 |
|